clinical trial · NCT07396870
A Phase 2 Study to Evaluate the Efficacy and Safety of LY03020 in Acutely Psychotic Participants With Schizophrenia
SchizophreniaLY03020Placebo
brief summary
This is a multicenter, randomized, double-blind, parallel-group, placebo-controlled, fixed-dosed phase II clinical study to evaluate the efficacy and safety of LY03020 in chinese acutely psychotic adult subjects with schizophrenia.
started
Mar 31, 2026
primary completion
Dec 31, 2027
completion
Dec 31, 2027
last updated
Feb 9, 2026
official title
A Multicenter, Randomized, Double-Blind, Parallel-Group, Placebo-Controlled, Fixed-Dosed Phase II Clinical Study to Evaluate the Efficacy and Safety of LPM787000048 Maleate Extended-Release Tablets (LY03020) in Acutely Psychotic Adult Subjects With Schizophrenia
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol